Last reviewed · How we verify
NCT06847035
Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement
NA trial testing Active Comparator in Skin Aging in 90 participants. Completed in 19 November 2024.
19 November 2024
Quick facts
| Lead sponsor | Shanghai Meifute Biotechnology Co., Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 25 July 2024 |
| Primary completion | 19 November 2024 |
| Estimated completion | 19 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Active Comparator — full drug profile →
- Placebo Comparator
Conditions studied
- Skin Aging — all drugs for Skin Aging →
Sponsor
Shanghai Meifute Biotechnology Co., Ltd
Who can join
Adults 35 to 55, female only, with Skin Aging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess if oral intake of collagen peptide can improve skin conditions such as skin thickness, density and firmness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Sustained Effects of Bioactive Collagen Peptides on Skin Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.
Wang Y, Zhu W, Luo W, Ma Y, et al · · 2025 · cited 1× · PMID 41311286 · DOI 10.1111/jocd.70565
Verify or expand the search:
- PubMed search for NCT06847035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active Comparator
Trials testing the same drug.
- NCT07300358 — Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System · NA · not yet recruiting
- NCT07168226 — Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 · Phase 2 · not yet recruiting
- NCT07188545 — Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney · active not recruiting
- NCT06457139 — Preventing T2DM After GDM With Immediate Postpartum Screening · NA · recruiting
- NCT07419763 — Intra Oral Appliance (IOA) Model Evaluating the Efficacy of Sensitive Toothpaste · NA · completed
Other recruiting trials for Skin Aging
Currently open trials in the same condition.
- NCT07381218 — Focused Ultrasound Treatment for Facial Skin Laxity · NA · active not recruiting
- NCT06900660 — Evaluation of the Skin-Beautifying Effects of Collagen Drinks · NA · active not recruiting
- NCT06804772 — A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the · NA · active not recruiting
- NCT06816069 — Study on Safety and Efficacy of Monopolar Radio Frequency Device for Facial Skin Tightening · NA · active not recruiting
- NCT06727292 — Biometrical Evaluation of the Efficacy of a Food Supplement Versus Placebo · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06847035 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Meifute Biotechnology Co., Ltd
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06847035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing